Zoetis announces agreement to acquire Basepaws, the innovative leader in pet genetics, to advance its range of precision animal health solutions

– Basepaws’ feline genomics database will enhance Zoetis’ research and development capabilities Informing future innovations from Zoetis

Barspany, NJ, June 07, 2022– (work wire) –Zoetis Inc. (NYSE: ZTS) today announced an agreement to acquire Basepaws, a privately owned pet genetics company that provides pet owners with genetic testing, analyzes and early health risk assessments that can help manage the health, wellness and quality of care for their pets. . This acquisition will strengthen Zoetis’ portfolio in animal micro-health and help shape the future pipeline for pet care innovations. The financial terms of the agreement were not disclosed.

This press release features multimedia. View the full version here: https://www.businesswire.com/news/home/20220606005978/ar/

Basepaws help pet owners and veterinarians understand the risk of disease in individual pets and can lead to more meaningful associations and increase the likelihood of early disease detection and treatment. (Source: Zoetis)

As a leading pet genetics genetics company, Basepaws provides easy-to-use genetic screening tools for early detection of disease risk in pets, as well as individual health and breed reports that can identify traits, biomarkers, and potential genetic conditions in pets. Basepaws help pet owners and veterinarians understand the risk of disease in individual pets and can lead to more meaningful associations and increase the likelihood of early disease detection and treatment.

“The Basepaws team has done an amazing job demonstrating how genetic testing and data can improve how we care for the pets in our lives,” said Abhay Nayak, Executive Vice President of Strategy, Rapid Growth and Commercial Development. “With the addition of Basepaws, Zoetis will continue to enhance our product suite of micro-animal health, across genetics, diagnostics, and data analytics for pets and livestock. We are also excited about how Basepaws’ Cat Genome and Microbiome Database can help advance research and development capabilities and inform the future of the pet care pipeline.” .

“Both Basepaws and Zoetis are made up of pet lovers with a passion for science, and our mission is to create better and longer lives for our pets through knowledge and data,” said Anna Skaya, CEO of Basepaws, which founded the company in 2017. Forward to expand our business and the impact of our genetic products through the global reach and R&D expertise of Zoetis, the global leader in animal health. We believe that together we can bring the benefits of a more proactive healthcare approach to pet parents around the world. “

Pioneering pet genetics with rich science and a start-up mindset

Basepaws has developed and marketed a comprehensive cat DNA test and the world’s first home oral health test for cats, with plans to expand into the canine market. Today, Basepaws genetic testing services are marketed primarily to pet owners in the United States, and include the popular Breed + Health Cat DNA test. Using a world-class cat genomic database, this test can estimate the genetic similarity of cats with more than 21 breeds and 4 breed regions, and provides results for more than 115 known cat genetic markers – 65 markers for hereditary health conditions and 50 markers for traits.

Basepaws also has one of the world’s largest feline oral and genomic genome databases and is a rich source for validating the health traits and conditions of today’s cats, informing future research and development efforts and goals. Zoetis’ R&D organization has brought game-changing innovations to pet care over the past 10 years in the field of dermatology, parasiticides, and pain, and the Basepaws database will help improve and inform the company’s pipeline and future goals.

About Basepaws

Basepaws is a genetics pet grooming company that builds early detection tests for health risks based on genetic and microbiome data. Basepaws is committed to companion animal health research, and has the world’s first in-house genetic testing platform for cats. The company was founded in 2017 by Anna Skaya, and is headquartered in Los Angeles, California. For more information visit www.basepaws.com.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by one goal: to take care of our world and humanity by advancing animal welfare. After 70 years of devising ways to predict, prevent, detect and treat animal diseases, Zoetis continues to stand by those who raise and care for animals around the world – from ranchers to veterinarians and pet owners. The company’s leading portfolio and pipeline of drugs, vaccines, diagnostics and technologies are making a difference in more than 100 countries. Zoetis, a Fortune 500 company, generated $7.8 billion in revenue in 2021 with approximately 12,100 employees. For more information visit www.zoetis.com.

Disclosure notices

forward-looking statements: This press release contains forward-looking statements that reflect Zoetis’ current views regarding: expectations regarding the performance of the acquired companies and our ability to integrate new business; expectations regarding the financial impact of acquisitions; business plans or prospects, future operating or financial performance, future direction, future operating models; research and development costs, timing and probability of success; expectations regarding products, approvals, or products under development and the expected timing of product launch; the impact of the global coronavirus (COVID-19) pandemic and any recovery from it on our business, supply chain, customers, and employees; future use of cash, dividend payments and share repurchases; the tax rate, tax regulations and any changes to them; and other events in the future. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove incorrect, actual results could differ materially from those contemplated in the forward-looking statement. Forward-looking statements speak only as of the date they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A list and additional description of risks, uncertainties and other matters can be added found in our Annual Report on Form 10-K for the fiscal year ending December 31, 2021, including the sections mentioned in “Forward-looking statements and factors that may affect future results” and “Element 1A. Risk Factors” in our quarterly reports on Form 10-Q and in our current reports in Form 8-K. These risks and uncertainties may be exacerbated by the global COVID-19 pandemic and its potential impact on the global economy and our business. These and subsequent deposits are available online at www.sec.govAnd the www.zoetis.comor at the request of Zoetis.

ZTS-COR
ZTS-IR
ZTS-FIN

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005978/ar/

Contacts

Media contact:
Invoice price
1-973-443-2742 (Q)
William.price@zoetis.com

Kristen Seely
1-974-443-2777 (Q)
Kristen.seely@zoetis.com

Anna Skaya
1-949-426-9229 (Q)
anna@basepaws.com

Investor contact
Steve Frank
1-973-822-7141
steve.frank@zoetis.com